8-K: Avanos Medical Reports Mixed Q4 and Full-Year 2023 Results Amidst Transformation

Avanos Medical reported a decrease in fourth-quarter and full-year net sales, while making progress on its transformation initiative.

Summary

• Avanos Medical announced its fourth quarter and full-year 2023 financial results, showing a 4.6% decrease in fourth-quarter net sales to $173.3 million compared to the prior year.
• Full-year net sales also decreased by 1.6% to $673.3 million.
• The company's fourth-quarter diluted earnings per share were $0.24, up from $0.21 a year ago, but adjusted diluted earnings per share decreased to $0.36 from $0.45.
• For the full year, the company reported a diluted loss per share of $0.21, compared to earnings per share of $0.46 in the prior year, while adjusted diluted earnings per share increased to $1.03 from $1.00.
• Free cash flow for the fourth quarter was an outflow of $3.4 million, and full-year free cash flow was $14.6 million, down from $71.6 million in 2022.
• The company completed the sale of its respiratory health business on October 2, 2023, and acquired Diros Technology, Inc. on July 24, 2023.
• Avanos expects 2024 net sales to be between $685 and $705 million, with adjusted diluted earnings per share between $1.30 and $1.45.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the decrease in sales and free cash flow, and the full-year loss per share. However, the company is making progress on its transformation initiative and has provided a positive outlook for 2024, which prevents a more negative score.

Positives

• The company made progress on its three-year transformation initiative.
• Adjusted diluted earnings per share for the full year increased to $1.03 from $1.00 in 2022.
• The acquisition of Diros Technology is expected to enhance the Pain Management and Recovery portfolio.
• The company expects organic growth between 3% to 6% in 2024.
• Adjusted EBITDA for the full year totaled $98.9 million, compared to $91.2 million in the prior year.

Negatives

• Fourth-quarter net sales decreased by 4.6% year-over-year.
• Full-year net sales decreased by 1.6% compared to the previous year.
• Fourth-quarter adjusted diluted earnings per share decreased to $0.36 from $0.45 in the prior year.
• The company reported a full-year diluted loss per share of $0.21.
• Free cash flow decreased significantly to $14.6 million for the full year, down from $71.6 million in 2022.
• Gross margin for the fourth quarter decreased to 54.8% from 56.7% a year ago.
• Operating profit in the quarter was $11.2 million compared to $16.6 million in the fourth quarter of 2022.

Risks

• The company faces risks related to economic conditions, pricing pressures, and supply chain disruptions.
• There are risks associated with the ongoing conflicts between Russia and Ukraine and in the Middle East.
• The company's ability to successfully execute its transformation process and achieve expected benefits is not guaranteed.
• The company is exposed to inflationary pressures and rising interest rates.
• Changes in foreign exchange markets could impact financial results.
• There are risks related to legislative and regulatory actions, including the EU MDR.
• The company faces potential product liability claims and compliance risks.

Future Outlook

Avanos expects 2024 net sales to be between $685 and $705 million, with adjusted gross profit margins between 59.5% and 60.5%, adjusted SG&A as a percentage of revenue between 41% and 42%, and adjusted diluted earnings per share between $1.30 and $1.45.

Management Comments

• Joe Woody, Avanos' chief executive officer, stated that they were very pleased with the overall execution on their transformation initiative last year.
• Woody believes they are poised to maintain positive momentum in their Digestive Health portfolio.
• Woody is confident that their strategy for the Pain Management and Recovery business will lead to sustainable growth in 2024.

Industry Context

Avanos' results reflect a challenging environment for medical device companies, with pressures on sales and profitability. The company's strategic shift towards focusing on core markets and divesting non-core assets is a common strategy in the industry to improve efficiency and growth prospects. The acquisition of Diros is in line with the trend of companies seeking to expand their product portfolios through strategic acquisitions.

Comparison to Industry Standards

• Avanos' revenue decline of 1.6% for the full year is worse than some of its peers in the medical device industry, which have seen modest growth.
• Companies like Medtronic and Stryker have reported positive revenue growth in their recent results, indicating that Avanos is underperforming in terms of sales.
• However, Avanos' focus on transformation and cost management is similar to strategies employed by other companies in the industry to improve profitability.
• The adjusted EBITDA of $98.9 million for the full year is lower than some of the larger players in the industry, but the company's focus on improving margins could lead to better results in the future.
• The acquisition of Diros is a strategic move similar to other companies acquiring smaller innovative firms to enhance their product offerings.

Stakeholder Impact

• Shareholders may be concerned about the decrease in sales and the full-year loss per share.
• Employees may be affected by the ongoing transformation process and cost management initiatives.
• Customers may benefit from the company's focus on innovative healthcare solutions.
• Suppliers may be impacted by changes in the company's supply chain.
• Creditors may be concerned about the decrease in free cash flow.

Next Steps

• The company will continue to execute its three-year transformation initiative.
• Avanos will focus on optimizing its commercial organization, transforming its product portfolio, and implementing cost management initiatives.
• The company will continue to efficiently deploy capital while maintaining a disciplined approach to M&A.
• Avanos will host a conference call to discuss the results.

Key Dates

Keywords

Avanos Medical, Financial Results, Transformation Initiative, Net Sales, Earnings Per Share, Free Cash Flow, Diros Technology, Respiratory Health, Pain Management, Digestive Health, Medical Devices